About Co-Diagnostics Inc
- Industry: Health Care
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://codiagnostics.com/
Frequently Asked Questions
What is the 52-week range for CODX?
The 52-week high is $46.5 and the 52-week low is $0.9057.
What is the P/E ratio for CODX?
The P/E ratio data is currently unavailable.
What is the dividend yield for CODX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -210.99%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -6523.11%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.50.
Analyst Recommendation Trends
Wall Street analyst consensus for CODX over the last few months:
Latest CODX News
Co-Diagnostics to Participate in Global Health Events During UN General Assembly Week
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that Seth Egan, Chief Commercialization Officer, will represent the Company at two global health events during the 81st Session of the United Nations General Assembly in New York City:
Co-Diagnostics to Participate in Global Health Roundtable on Ebola and Outbreak Innovation
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that Seth Egan, Chief Commercialization Officer, will participate in the Global Health Technologies Coalition (GHTC) and Adjuvant Capital roundtable discussion on September 22, 2026, in New York, NY.
Co-Diagnostics to Participate in Joint WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 2026
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will participate in the upcoming joint WHO/Unitaid/UNAIDS Annual Consultation Meeting. Joseph Featherstone, Executive Vice President of Business Development, will represent Co-Dx at the annual meeting, which will be held at the World Health Organization (WHO) headquarters in Geneva, Switzerland,
Co-Diagnostics, Inc. (CODX) Shareholder/Analyst Call Transcript
Co-Diagnostics, Inc. (CODX) Shareholder/Analyst Call September 16, 2026 10:30 AM EDTCompany ParticipantsDwight Egan - Chairman, CEO &...
Co-Diagnostics, Inc. (CODX) Shareholder/Analyst Call - Slideshow
2026-09-16. The following slide deck was published by Co-Diagnostics, Inc.
Co-Diagnostics and ReadyGo Collaborate to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests and ReadyGo Diagnostics Ltd. ("ReadyGo"), a UK-based developer of field sample-preparation technology, today announced that the companies are collaborating to evaluate the potential use of ReadyGo's sample-preparation technology with the Co-Dx PCR platform for blood-based molecular testing at the point of need, with an
Co-Diagnostics to Hold Press Conference
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will host a press conference and live webcast Wednesday, Sept. 16, 2026, at 10:30 a.m. Eastern Time.
Co-Diagnostics Enters Material Transfer Agreement With ReadyGo Diagnostics To Evaluate Sample Preparation Technologies For Co-Dx PCR Platform; Material Transfer Agreement Does Not Obligate Either Party To Enter Into Any Development, Supply, Commercialization Or Other Commercial Arrangement
In August 2026, Co-Diagnostics, Inc. (the "Company") entered into a material transfer agreement with ReadyGo Diagnostics Ltd ("ReadyGo") to evaluate the potential compatibility of certain ReadyGo sample
Stock Market Today: S&P 500, Dow, Nasdaq 100 Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction— ASML, NVS, CASY in Focus (UPDATED)
Stock Market Today: S&P 500, Dow Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction— ASML, NVS, CASY in Focus
United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday
Stocks in focus: UNFI and ABM earnings, Novartis trial miss, Co-Diagnostics CFO change, and Casey’s earnings expected.
Co-Diagnostics CFO Brian Brown Departs Company; Appoints Daniel Bohrer As Principal Financial Officer, Effective September 2, 2026
On September 2, 2026, Co-Diagnostics, Inc. (the "Company") and Brian Brown, the Company’s Chief Financial Officer, determined that Mr. Brown’s last day of employment with the Company would be September 2, 2026
Co-Diagnostics Launches Integrated Cloud and Mobile Infrastructure in India
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the launch of its integrated cloud infrastructure in India. The deployment is intended to support the Company's ongoing clinical studies for its point-of-care Mycobacterium tuberculosis (MTB) test while establishing the digital foundation for future deployment of the Co-Dx® PCR platform* throughout the
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-05-23 | Abbott Richard David | -1,890 | - | - |
| 2026-05-23 | Abbott Richard David | -680 | $5.07 | $3,448 |
| 2026-05-23 | Abbott Richard David | +1,890 | - | - |
| 2026-05-23 | Brown Brian Lee | -3,750 | - | - |
| 2026-05-23 | Brown Brian Lee | -1,350 | $5.07 | $6,845 |
| 2026-05-23 | Brown Brian Lee | +3,750 | - | - |
| 2026-05-23 | Durenard Eugene | -1,695 | - | - |
| 2026-05-23 | Durenard Eugene | +1,695 | - | - |
| 2026-05-23 | Murphy Edward L. | -1,695 | - | - |
| 2026-05-23 | Murphy Edward L. | +1,695 | - | - |
| 2026-05-23 | Egan Dwight H | -4,584 | - | - |
| 2026-05-23 | Egan Dwight H | -1,633 | $5.07 | $8,279 |
| 2026-05-23 | Egan Dwight H | +4,584 | - | - |
| 2026-05-23 | NELSON JAMES B | -1,695 | - | - |
| 2026-05-23 | NELSON JAMES B | +1,695 | - | - |
| 2026-05-23 | SERBIN RICHARD S | -1,695 | - | - |
| 2026-05-23 | SERBIN RICHARD S | +1,695 | - | - |
| 2025-11-23 | Abbott Richard David | -56,667 | - | - |
| 2025-11-23 | Abbott Richard David | -17,200 | $0.35 | $6,020 |
| 2025-11-23 | Abbott Richard David | +56,667 | - | - |
| 2025-11-23 | Brown Brian Lee | -134,167 | - | - |
| 2025-11-23 | Brown Brian Lee | -40,723 | $0.35 | $14,253 |
| 2025-11-23 | Brown Brian Lee | +134,167 | - | - |
| 2025-11-23 | Durenard Eugene | -57,499 | - | - |
| 2025-11-23 | Durenard Eugene | +57,499 | - | - |
| 2025-11-23 | Murphy Edward L. | -57,499 | - | - |
| 2025-11-23 | Murphy Edward L. | +57,499 | - | - |
| 2025-11-23 | Egan Dwight H | -163,333 | - | - |
| 2025-11-23 | Egan Dwight H | -49,575 | $0.35 | $17,351 |
| 2025-11-23 | Egan Dwight H | +163,333 | - | - |
| 2025-11-23 | NELSON JAMES B | -57,499 | - | - |
| 2025-11-23 | NELSON JAMES B | +57,499 | - | - |
| 2025-11-23 | SERBIN RICHARD S | -57,499 | - | - |
| 2025-11-23 | SERBIN RICHARD S | +57,499 | - | - |